2025 年 05 月 02 日 公司研究 评级：增持(维持) 研究所： 证券分析师： 李永磊 S0350521080004 liyl03@ghzq.com.cn 证券分析师： 董伯骏 S0350521080009 dongbj@ghzq.com.cn 证券分析师： 陈云 S0350524070001 cheny17@ghzq.com.cn [Table_Title] 毛利率改善，2025 年一季度业绩同环比提高 ——回天新材（300041）2024 年年报及 2025 年一季报点评 最近一年走势 | 相对沪深 300 | 表现 | | 2025/04/30 | | --- | --- | --- | --- | | 表现 | 1M | 3M | 12M | | 回天新材 | -4.8% | -1.5% | 5.4% | | 沪深 300 | -3.7% | -1.2% | 4.6% | | 市场数据 | | | 2025/04/30 | | 当前价格（元） | | | 8.45 | | 周价格区间（元） 52 | | | 6.92-10.70 | | 总市值（百万） | | | 4,727.22 | | 流 ...

证券研究报告 | 公司点评报告 2025 年 05 月 02 日 奇安信（688561.SH） Q1 企稳向好，紧抓回款与现金流管理 TMT 及中小盘/计算机 25Q1 公司收入企稳、新签订单额同比增长 16%，下游客户需求出现复苏迹 象。公司紧抓回款与现金流管理，AI 安全为行业贡献业务新增量。 ❑ 风险提示：政策不及预期、下游客户需求不及预期、行业竞争加剧。 财务数据与估值 | 会计年度 | 2023 | 2024 | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入(百万元) | 6442 | 4349 | 4697 | 5167 | 5684 | | 同比增长 | 4% | -32% | 8% | 10% | 10% | | 营业利润(百万元) | 26 | (1432) | (315) | 56 | 152 | | 同比增长 | -226% | -5656% | -78% | -118% | 170% | | 归母净利润(百万元) | 72 | (1379) | (307) | 50 | 142 | | 同比增 ...

公司研究 证 券 研 究 报 告 芯源微（688037）2024 年报&2025 年一季报点评 强推（维持） 订单稳健增长，化学清洗&Track 进展顺利 目标价：122.0 元 事项： 评论： [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 1,754 | 2,046 | 2,748 | 3,598 | | 同比增速(%) | 2.1% | 16.7% | 34.3% | 30.9% | | 归母净利润(百万) | 203 | 261 | 418 | 606 | | 同比增速(%) | -19.1% | 28.7% | 60.2% | 45.0% | | 每股盈利(元) | 1.01 | 1.30 | 2.08 | 3.01 | | 市盈率(倍) | 95 | 73 | 46 | 32 | | 市净率(倍) | 7.1 | 6.7 | 6.0 | 5.3 | 资料来源：公司公告，华创证券预测 注：股价为 2025 年 4 月 30 日 ...

[Table_Tag] [Table_Summary] 投资要点 证券研究报告·公司点评报告·家电零部件Ⅱ 德业股份（605117） 2024 年报及 2025 年一季报点评：Q1 业绩略 超预告上限，25 年户储&工商储多点开花 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 7480 | 11206 | 14090 | 16908 | 19782 | | 同比（%） | 25.59 | 49.82 | 25.73 | 20.00 | 17.00 | | 归母净利润（百万元） | 1791 | 2960 | 3848 | 4647 | 5490 | | 同比（%） | 18.03 | 65.29 | 29.99 | 20.76 | 18.14 | | EPS-最新摊薄（元/股） | 2.77 | 4.58 | 5.96 | 7.19 | 8.50 | | P/E（现价&最新摊薄） | 31.09 | 18.81 ...

Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 42.88 CNY, compared to the current stock price of 36.50 CNY [4]. Core Insights - The company achieved a revenue of 2.513 billion CNY in 2024, marking a year-on-year growth of 33.13%, and recorded a net profit of 112 million CNY, indicating its first profitable year since listing [1][11]. - The core product, the recombinant factor VIII product Anjain®, saw stable sales with a revenue of 1.89 billion CNY in 2024, reflecting a growth of 6.18% despite price pressures from regional procurement [3][9]. - The company is actively expanding its overseas market presence, having signed agreements with partners in over ten "Belt and Road" countries and obtaining regulatory approvals for product launches in Pakistan and Indonesia [3][9]. Financial Performance - In Q1 2025, the company reported a revenue of 520 million CNY, a decrease of 15.15% year-on-year, with a net profit of 64 million CNY, down 14.06% [1]. - The gross margin for 2024 was 95.91%, a slight decline of 1.20 percentage points, while the gross margin for the core product Anjain® was 96.89% [2]. - The company’s R&D expenses in 2024 were 911 million CNY, a decrease of 20.64%, primarily due to most products being in early clinical research stages [2][10]. Market Strategy - The company has implemented flexible market strategies to ensure compliance with procurement pricing and to expand market share for Anjain® [3]. - The sales of antibody drugs, including Anpingxi® and two biosimilars, exceeded 620 million CNY in 2024, showing a significant growth of 499.80% [9]. - The company is focusing on real-world studies to gather clinical data, enhancing treatment protocols and patient confidence [9]. Future Projections - Revenue growth is projected at 16.9%, 20.8%, and 16.4% for 2025 to 2027, with net profit growth expected at 86.1%, 114.0%, and 62.6% respectively [11][12].

证券研究报告 | 年报点评报告 gszqdatemark 2025 05 02 年 月 日 地素时尚（603587.SH） 2025Q1 收入降幅收窄，期待全年业绩稳健增长 2024 年公司收入同比-16%/归母净利润同比-39%。1）2024 年公司收入为 22.2 亿元， 同比-16%；归母净利润为 3 亿元，同比-39%；扣非归母净利润为 2.5 亿元，同比-46%；非 经常损益主要系政府补助及公允价值变动损益。2）盈利质量：全年毛利率同比+0.4pct 至 74.8%；销售/管理/财务费用率同比分别+5.3/+1.6/+0.1pct 至 45.7%/8.7%/-2.0%（我们 判断销售费用率提升主要系直营渠道存在刚性费用）；净利率同比-5.0pct 至 13.7%。3）单 四季度：2024Q4 收入为 6.1 亿元，同比-25%；归母净利润为 0.2 亿元，同比-69%；扣非归 母净利润为 0.1 亿元，同比-89%。4）公司 2024 年合计拟分配现金股利 2.35 亿元，股利支 付率约为 78%，以 2025 年 4 月 30 日收盘价计算的股息率约为 4.2%。 2025Q1 公司收入同比-11 ...

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Views - The company reported a revenue of 4.115 billion yuan in Q1 2025, a year-on-year decrease of 2.4%, while the net profit attributable to shareholders reached 148 million yuan, a significant increase of 338.3% year-on-year [1] - The chicken segment showed resilience with sales of 303,000 tons, up 3.1% year-on-year, despite a decline in average selling price by 4% to 9,759 yuan per ton [2] - The company has successfully managed costs, achieving a 10% reduction in comprehensive meat production costs compared to the same period in 2024, aided by the self-developed breed "Shengze 901Plus" [2] - The C-end business experienced rapid growth, with retail sales exceeding 30% year-on-year growth, despite overall pressure in the retail sector [3] - The company expects net profits to reach 990 million yuan, 1.06 billion yuan, and 1.21 billion yuan for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 37.1%, 6.8%, and 13.8% [3] Financial Summary - For 2025, the company is projected to achieve a revenue of 21.232 billion yuan, with a year-on-year growth rate of 14.2% [5] - The net profit attributable to shareholders is expected to be 993 million yuan in 2025, with a growth rate of 37.1% [5] - The earnings per share (EPS) for 2025 is estimated at 0.80 yuan, with a price-to-earnings (P/E) ratio of 20.7x [5]

Investment Rating - The investment rating for the company is "Accumulate-A" with a target price of 68.33 CNY over the next six months [3][4]. Core Views - The company's performance in Q1 2025 was under pressure, with a revenue of 401 million CNY, a year-on-year decline of 46.76%, and a net loss of 53 million CNY. This decline is attributed to the vaccine segment facing market adjustments, government procurement, and the expansion of the nine-valent HPV vaccine age group, leading to lower-than-expected sales [1]. - The nine-valent HPV vaccine is in the listing application stage, with expectations for its contribution to future revenue. The clinical trials are progressing well, and commercial production conditions are ready. The company anticipates that the launch of this vaccine will help restore its operational performance [2]. Summary by Sections Financial Performance - In 2025, the company is projected to achieve revenues of 3.17 billion CNY, 11.4 billion CNY in 2026, and 28.63 billion CNY in 2027. Net profits are expected to be 350 million CNY, 2.13 billion CNY, and 6.01 billion CNY for the same years respectively [3][10]. - The company’s revenue growth rate is forecasted to be -50.7% in 2023, -59.3% in 2024, followed by a recovery to 41.0% in 2025, 259.9% in 2026, and 151.3% in 2027 [11]. Market Potential - The nine-valent HPV vaccine is expected to reach a peak sales value of 22.8 billion CNY, assuming a cumulative vaccination penetration rate of over 50% among eligible women. The estimated valuation of the company based on this product is 86.5 billion CNY, considering a 4x price-to-sales ratio and a 95% success rate for the product launch [3][10]. Stock Performance - As of April 30, 2025, the stock price was 65.41 CNY, with a 12-month price range of 63.3 to 83.8 CNY. The total market capitalization is approximately 82.75 billion CNY [4][5].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company has faced operational pressure over the past 24 years, but there has been an improvement in profit per ton in Q1 2025 compared to the previous quarter [1][11] - The company’s total revenue and net profit for 2024 were 21.5 billion and 770 million yuan, respectively, reflecting a year-on-year decline of 9% and 35% [5][11] - In Q1 2025, the company achieved total revenue of 4.8 billion yuan, a year-on-year increase of 9%, while net profit decreased by 33% [5][11] Summary by Sections Revenue and Profitability - In 2024, the company’s steel structure business generated revenue of 20.8 billion yuan, down 9% year-on-year, with a sales volume of 4.33 million tons, up 2% [6] - The average price per ton was 4,803 yuan, a decrease of 10% year-on-year due to falling steel prices [6] - The gross profit margin for the steel structure business was 17.1 billion yuan, down 17% year-on-year, with a gross profit per ton of 394 yuan, down 18% [6] Operational Performance - The company signed new orders worth 28.3 billion yuan in 2024, a decrease of 5% year-on-year, with a production volume of 4.51 million tons [6] - The production and sales rate was 96.1%, an increase of 1.2 percentage points year-on-year [6] Q1 2025 Performance - In Q1 2025, the company produced 1.05 million tons, with a sales volume of approximately 1 million tons [10] - The gross profit per ton was 475 yuan, down 57% year-on-year, primarily due to a decline in steel prices [10] - The company reported a significant reduction in R&D expenses, indicating a potential peak in the intensity of its smart transformation efforts [10] Financial Forecasts - The company’s net profit forecasts for 2025 and 2026 have been adjusted to 1.03 billion yuan and 1.15 billion yuan, respectively, reflecting a downward revision of 21% and 30% [11] - The report anticipates improvements in profitability as the company’s smart transformation progresses [11] Market Position - The company’s stock price has experienced a significant correction, and the improvement in ton profit in Q1 2025 supports the "Buy" rating [11]

公司研究 资料来源：公司公告，华创证券预测 注：股价为 2025 年 4 月 30 日收盘价 航空 2025 年 05 月 02 日 当前价：22.19 元 华创证券研究所 证券分析师：吴一凡 证 券 研 究 报 告 中信海直（000099）2025 年一季报点评 推荐（维持） 最佳一季度业绩表现，与中信金租、峰飞航空展开 eVTOL 领域合作 [主要财务指标 ReportFinancialIndex] | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 2,163 | 2,378 | 2,634 | 2,923 | | 同比增速(%) | 9.8% | 9.9% | 10.8% | 11.0% | | 归母净利润(百万) | 303 | 360 | 400 | 436 | | 同比增速(%) | 26.8% | 18.7% | 11.1% | 9.0% | | 每股盈利(元) | 0.39 | 0.46 | 0.52 | 0.56 | | 市盈率(倍) | 57 | 48 | 43 | 39 | ...